AN2 Therapeutics Inc (ANTX) - Total Assets
Based on the latest financial reports, AN2 Therapeutics Inc (ANTX) holds total assets worth $81.68 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
AN2 Therapeutics Inc - Total Assets Trend (2019–2025)
This chart illustrates how AN2 Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see how much is AN2 Therapeutics Inc worth for the company's overall valuation and market capitalisation.
AN2 Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
AN2 Therapeutics Inc's total assets of $81.68 Million consist of 96.8% current assets and 3.3% non-current assets. Review ANTX total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.2% |
| Accounts Receivable | $900.00K | 1.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how AN2 Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See AN2 Therapeutics Inc stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AN2 Therapeutics Inc's current assets represent 96.8% of total assets in 2025, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 32.2% of total assets in 2025, down from 98.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 1.5% of total assets.
AN2 Therapeutics Inc Competitors by Total Assets
Key competitors of AN2 Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
AN2 Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.32 | 31.96 | 17.70 |
| Quick Ratio | 14.32 | 31.96 | 17.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $74.41 Million | $65.41 Million | $56.71 Million |
AN2 Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between AN2 Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.93 |
| Latest Market Cap to Assets Ratio | 2.98 |
| Asset Growth Rate (YoY) | -32.7% |
| Total Assets | $61.95 Million |
| Market Capitalization | $184.91 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values AN2 Therapeutics Inc's assets at a significant premium (2.98x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: AN2 Therapeutics Inc's assets decreased by 32.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for AN2 Therapeutics Inc (2019–2025)
The table below shows the annual total assets of AN2 Therapeutics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $61.95 Million | -32.73% |
| 2024-12-31 | $92.09 Million | -33.63% |
| 2023-12-31 | $138.74 Million | +35.28% |
| 2022-12-31 | $102.56 Million | +57.02% |
| 2021-12-31 | $65.32 Million | +1442.65% |
| 2020-12-31 | $4.23 Million | -25.72% |
| 2019-12-31 | $5.70 Million | -- |
About AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15… Read more